Floatz logo

XENON

Bipolar Depression

Massachusetts General HospitalSmall moleculeEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
81/ 100

Competitive context

28 Active assets in the Bipolar Depression cohort.

Asset / SponsorPhaseRating
Lurasidone
NeuroRx, Inc.
Phase 4A
LITHIUM, ELEMENTAL
Dr. Inge Winter
Phase 4BBB
Seroquel®
Dr. Inge Winter
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Joshua Rosenblat
Phase 4BBB
LAMOTRIGINE
Stony Brook University
Phase 4BBB

View all 50 →

Same molecule, other indications

XENON is also rated in:

cystic fibrosisDormant
BB
Indicative ·
65 / 100
View asset →
asthmaDormant
B
Indicative ·
63 / 100
View asset →
pulmonary fibrosisDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →